(Pro)renin receptor inhibition attenuated liver steatosis, inflammation, and fibrosis in mice with steatohepatitis. Issue 10 (5th September 2022)

• Record Type: Journal Article
• Authors: Hsieh, Yun‐Cheng; Wu, Pei‐Shan; Lin, Yi‐Tsung; Huang, Yi‐Hsiang; Hou, Ming‐Chih; Lee, Kuei‐Chuan; Lin, Han‐Chieh
• Is Part Of: FASEB journal. Volume 36:Issue 10(2022)
• Page Start: n/a
• Page End: n/a
• Publication Date: 2022-09-05
• Subjects: chronic liver injury -- gene silencing -- handle region peptide -- lipid metabolism -- nonalcoholic fatty liver disease; Biology -- Periodicals; Biology, Experimental -- Periodicals; 570
• DOI: 10.1096/fj.202200594R
• Languages: English
• ISSNs: 0892-6638

Abstract

Abstract: The (Pro)renin receptor (PRR) is reportedly involved in hepatic lipid metabolism and hepatocyte PRR knockdown protects mice against hepatosteatosis. However, the impact of PRR inhibition on liver inflammation and fibrosis in nonalcoholic steatohepatitis (NASH) remains unclear. Herein, C57BL/6 mice were fed a normal chow diet or fast food diet (FFD) for 24 weeks. Lentivirus‐mediated PRR short hairpin RNA (shRNA) or handle region peptide (HRP), a PRR blocker, was administered for PRR inhibition. Mouse primary hepatocytes were cultured with palmitic acid, prorenin, siRNA‐targeted PRR, and HRP. In FFD‐fed mice, PRR inhibition via lentivirus‐mediated PRR knockdown or HRP significantly attenuated liver steatosis, inflammation, and fibrosis. Mechanistically, PRR knockdown or HRP decreased hepatic acetyl‐CoA carboxylase (ACC) abundance and upregulated peroxisome proliferator‐activated receptor‐alpha (PPARα). HRP treatment also decreased hepatic PRR expression. In addition, intrahepatic oxidative stress, apoptosis and inflammatory cell recruitment were ameliorated by PRR knockdown or HRP treatment, along with suppression of proinflammatory cytokine expression. PRR inhibition downregulated the hepatic expression of profibrotic factors, as well as TGF‐β1/SMAD3 pathway. In primary mouse hepatocytes, PRR knockdown with siRNA or HRP downregulated cellular ACC and increased PPARα expression. In conclusion, our findings revealed that PRR inhibition attenuated hepatic steatosis, inflammation, and fibrosis in mice with NASH. Accordingly, targeting PRR signaling may serve as a potential treatment for NASH.